Pneumonia Therapeutics Market

Pneumonia Therapeutics Market by Products (Drugs [Branded {Quinolones, Aminopenicillins, Macrolides, B-lactamase Inhibitors, Cephalosporins, Tetracyclines, Glycopeptide Antibiotics, Carbapenems, and Others}, Generics {Quinolones, Macrolides, and Others}], Vaccines, and Oxygen Therapy) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2254
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 39
  • No. Of Pages: 184
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global pneumonia therapeutics market size is expected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the high incidence of pneumonia in the world. Additionally, the high awareness in the population and government interest in the disease treatment.

Pneumonia Therapeutics Market key Takeaways

Pneumonia is a type of infection that results in inflammation in air sacs in one or both lungs. In pneumonia, the air sacs gets filled with pus or fluid. The infection can be deadly to any person but it is widely occurred particularly in children, infants, and people of age 65 or above. Symptoms of the disease include fever, chills, cough with pus or phlegm, and troubled breathing. Antibiotics are used to treat different forms of pneumonia. Vaccines can also be used to prevent pneumonia. The various types of pneumonia include Hospital-Acquired Pneumonia (Nosocomial Pneumonia), Pneumocystis jiroveci Pneumonia (PJP), Chlamydial Pneumonias, Viral Pneumonia, and Ventilator-Associated Pneumonia, Aspiration Pneumonitis and Pneumonia, and Community-Acquired Pneumonia (CAP). As per a report of the World Health Organization (WHO), the annual cases of pneumonia is around 150 million cases, out of which 7% to 13% require intensive care. WHO also suggest, 95% of all pneumonia cases occur in children in developing nation. It is responsible for 15% of all deaths of children under 5 years old, which was 800000 deaths of children in 2017.

The outbreak of COVID-19 pandemic showed positive impact on the market. The collaboration between biotech & pharmaceutical companies with governments across the world to work for development of COVID-19 vaccine and medicines is a key aspect of the market expansion. This boosted the R&D activities gained pace and resulted into development of 115 vaccine candidates along with 155 molecules in the pipeline. The COVID-19 resulted in high demand of certain drugs in the world, which results in creating more opportunities for manufacturers of COVID-19 management drugs. The upsurge in demand for vaccine and drugs for the COVID-19 treatment, the pharmaceutical and biotechnology industry is anticipated to register a significant growth rate in the near future.

Market Trends, Drivers, Restraints, and Opportunities

  • High number of ongoing clinical trials for the development of novel drugs is acting as a key factor for the market growth.
  • Increased funding in the market segment for the R&D activities is projected to fuel the market expansion. For example, Bill & Melinda Gates Foundation is the organization that funds for the treatment of neonatal pneumococcal disease as well as development of new vaccines.
  • Increasing in the cases of resistant strains which is resulting in the demand for newer antibiotics is driving the market growth during the forecast period.
  • Inappropriate diagnosis of pneumonia and lack of new drugs are proving to be key restraints for the growth of the market.
  • High prevalence of disease and increasing research & development activities in the field are creating huge opportunity of the market growth in the near future.

Scope of the Report

The report on the global pneumonia therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Pneumonia Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Drugs [Branded {Quinolones, Aminopenicillins, Macrolides, B-lactamase Inhibitors, Cephalosporins, Tetracyclines, Glycopeptide Antibiotics, Carbapenems, and Others}, Generics {Quinolones, Macrolides, and Others}], Vaccines, and Oxygen Therapy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Pfizer Inc.; Merck & Co; Sanofi; SetLance SRL; Nabriva Therapeuticals AG; Novartis AG; and Eli Lilly & Company

 

Market Segment Insights

Vaccine segment is expected to grow at a rapid pace

Based on products, the global pneumonia therapeutics market is divided into drugs, generics, vaccines, and oxygen therapy. The drug segment is further bifurcated into branded and generics. The branded drugs segment is further classified into quinolones, tetracyclines, aminopenicillins, macrolides, b-lactamase inhibitors, glycopeptide antibiotics, carbapenems, cephalosporins, and others. Meanwhile, the generic segment is segregated into quinolones, macrolides, and others. The vaccine segment is expected to grow at a rapid pace in the coming years owing to high demand for vaccines due to the high cost of drug therapy, high resistance of drugs, and high mortality rate. The high effectiveness of vaccines and high interest of regulatory authorities in vaccination are anticipated to propel the market segment at a substantial rate.

The drug segment is expected to exhibit a fast growth pace in the near future owing to the increasing demand of generic drugs. As the large number of patent expiration of blockbuster drug is occurring in the recent times, which has resulted to increase the demand for generic medicines in the market. These factors are driving the market segment in the projected time.

The oxygen therapy segment is estimated to account for a major market share in the coming years due to high urgency to accept systems for efficient clinical management and important in reducing complications. This is expected to boost the demand for oxygen therapy to manage pneumonia disease. Increased in number of randomized controlled trials for identifying the effect of oxygen therapy in intensive care units are proving to be major driver of the market segment during the forecast period.

Pneumonia Therapeutics Market by products

North America is anticipated to constitute a major market share

In terms of regions, the global pneumonia therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a major market share during the forecast period due to the rising old aged population and rising drug resistance in children & adults that intensifies the need for development of advanced therapeutics. As a result, major market players are funding on R&D for new product development activities in the region. Additionally, several government initiatives to prevent as well as treatment of pneumonia are accounted for putting a positive impact in the market in the North America. For example, the Integrated Global Action Plan for Pneumonia and Diarrhoea by UNICEF and WHO is focused at reducing child deaths due to pneumonia and diarrhoea.

However, the market of Asia Pacific is anticipated to register a substantial growth rate during the forecast period. The rise in prevalence of the disease, high cases of antimicrobial resistance, unmet patient needs, and growth in disorders resulting in weakening of immunity in the region are key drivers for the regional market growth. Rising interest in vaccination and recognizing the disease as a deadly disease due to high mortality & morbidity are the key factors to positively impact the regional market growth. For example, the government of India included pneumococcal vaccines in the Universal Immunization Program.

Pneumonia Therapeutics Market by Regions

Segments

Segments Covered in the Report
The global pneumonia therapeutics market has been segmented on the basis of

Products

  • Drugs
    • Branded
      • Quinolones
      • Aminopenicillins
      • Macrolides
      • B-lactamase Inhibitor
      • Cephalosporins
      • Tetracyclines
      • Glycopeptide Antibiotics
      • Carbapenems
      • Others
    • Generics
      • Quinolones
      • Macrolides
      • Others
  • Vaccines
  • Oxygen Therapy

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Pfizer Inc.
  • Merck & Co
  • Sanofi
  • SetLance SRL
  • Nabriva Therapeuticals AG
  • Novartis AG
  • Eli Lilly & Company

Competitive Landscape

Key players competing in the global pneumonia therapeutics market are Novartis AG; Pfizer Inc.; Merck & Co; SetLance SRL; Nabriva Therapeuticals AG; Sanofi; and Eli Lilly & Company. The pneumococcal vaccine V114 that is currently under investigation in phase II trials is developed by Merck & Co., Inc. Likewise, a new drug (GSK2140944) is under phase II trials is developed by GlaxoSmithKline plc is for the treatment of community-acquired bacterial pneumonia.

Pneumonia Therapeutics Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pneumonia Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Pneumonia Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Pneumonia Therapeutics Market - Supply Chain
  4.5. Global Pneumonia Therapeutics Market Forecast
     4.5.1. Pneumonia Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Pneumonia Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Pneumonia Therapeutics Market Absolute $ Opportunity
5. Global Pneumonia Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Pneumonia Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Pneumonia Therapeutics Demand Share Forecast, 2019-2026
6. North America Pneumonia Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Pneumonia Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Pneumonia Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Pneumonia Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Pneumonia Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Pneumonia Therapeutics Demand Share Forecast, 2019-2026
8. Europe Pneumonia Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Pneumonia Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Pneumonia Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Pneumonia Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Pneumonia Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Pneumonia Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Pneumonia Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Pneumonia Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Pneumonia Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Pneumonia Therapeutics Market: Market Share Analysis
  11.2. Pneumonia Therapeutics Distributors and Customers
  11.3. Pneumonia Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Pfizer Inc.
     11.4.2. Merck & Co
     11.4.3. Sanofi
     11.4.4. SetLance SRL
     11.4.5. Nabriva Therapeuticals AG
     11.4.6. Novartis AG
     11.4.7. Eli Lilly & Company

Segments Covered in the Report
The global pneumonia therapeutics market has been segmented on the basis of

Products

  • Drugs
    • Branded
      • Quinolones
      • Aminopenicillins
      • Macrolides
      • B-lactamase Inhibitor
      • Cephalosporins
      • Tetracyclines
      • Glycopeptide Antibiotics
      • Carbapenems
      • Others
    • Generics
      • Quinolones
      • Macrolides
      • Others
  • Vaccines
  • Oxygen Therapy

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Pfizer Inc.
  • Merck & Co
  • Sanofi
  • SetLance SRL
  • Nabriva Therapeuticals AG
  • Novartis AG
  • Eli Lilly & Company

Key players competing in the global pneumonia therapeutics market are Novartis AG; Pfizer Inc.; Merck & Co; SetLance SRL; Nabriva Therapeuticals AG; Sanofi; and Eli Lilly & Company. The pneumococcal vaccine V114 that is currently under investigation in phase II trials is developed by Merck & Co., Inc. Likewise, a new drug (GSK2140944) is under phase II trials is developed by GlaxoSmithKline plc is for the treatment of community-acquired bacterial pneumonia.

Pneumonia Therapeutics Market by key players

Buy Report